VivekRoyMD

Hematology • Jacksonville, FL

Professor of Medicine, Mayo College of Medicine

Join to view full profile

Dr. Roy is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Roy's full profile

Already have an account?

Office
4500 San Pablo Road S
Jacksonville, FL 32224

Education & Training

University of MinnesotaFellowship, Hematology and Medical Oncology, 1993 - 1996
UMass Chan Medical SchoolResidency, Internal Medicine, 1991 - 1993
All India Institute of Medical SciencesClass of 1980

Certifications & Licensure

AZ State Medical License 2000 - Present
FL State Medical License 2001 - 2025
MN State Medical License 1994 - 2025
OK State Medical License 1996 - 2005
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Fellow (FACP) American College of Physicians, 2002

Clinical Trials

Docetaxel, Carboplatin, and Pegfilgrastim in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer Start of enrollment: 2005 Aug 01
Completed
Phase 2
ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer Start of enrollment: 2005 Aug 01
Completed
Phase 2
Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma Start of enrollment: 2003 Jul 01
Completed
Phase 3
Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2005 Jun 01
Completed
Phase 1, Phase 2
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis Start of enrollment: 2007 Dec 01
Completed
Phase 2
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer Start of enrollment: 2007 Dec 01
Terminated
Phase 2
Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Start of enrollment: 2010 Feb 01
Completed
Phase 1, Phase 2
Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2011 Sep 01
Completed
Phase 1, Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Roles: Contact, Principal Investigator
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib Start of enrollment: 2012 Jan 31
Active, not recruiting
Phase 2
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) Start of enrollment: 2021 Apr 20
Terminated
Phase 1, Phase 2
Roles: Principal Investigator
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma Start of enrollment: 2023 Feb 22
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

10 citations
Hematopoietic stem cells from poor and good mobilizers are qualitatively equivalent
Liuyan Jiang, Sunny Malik, Mark R. Litzow, Dennis A. Gastineau, Ivana N. Micallef
Transfusion. 2012-03-01
47 citations
Efficacy and cost‐benefit analysis of risk‐adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization
Prakash Vishnu, Vivek Roy, Athena Paulsen, Abba C. Zubair
Transfusion. 2012-01-01
176 citations
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.
Shaji Kumar, Betsy LaPlant, Wee Joo Chng, Jeffrey A. Zonder, Natalie S. Callander
Blood. 2015-01-15

Journal Articles

Targeting CD38 with Daratumumab Is Lethal to Waldenström Macroglobulinaemia Cells
Richard Furman, Stephen M Ansell, Sikander Ailawadhi, Thomas E Witzig, Vivek Roy, Taimur Sher, Liuyan Jiang, British Journal of Haematology
Utilization of Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Myeloma: A Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consen...
John A Lust, Shaji K Kumar, Morie A Gertz, P Leif Bergsagel, Angela Dispenzieri, Francis K Buadi, Prashant Kapoor, Angela A Mayo, Wilson I Gonsalves, Rafael Fonseca, R..., Nature

Abstracts/Posters

Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
Vivek Roy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Trends in Early Mortality from Multiple Myeloma (MM): A Population-Based Analysis
Vivek Roy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Sociodemographic and Clinical Characteristics Associated with PatientÍs Decision to Refuse Multiple Myeloma (MM) Treatment, and Its Impact on Outcomes
Vivek Roy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Population-Based Analysis of Predictors of Survival and Trends in Outcomes of Elderly Patients with Multiple Myeloma (MM)
Vivek Roy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Disparities and Their Impact on the Adoption of Health Information Technology (HIT) in Minority Cancer Patients and Caregivers
Vivek Roy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Computational Modelling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment Outcome
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Sharing Mayo Clinic: “Divine Design” Gives Multiple Myeloma Patient Transplant, Care at HomeSeptember 5th, 2021
“Divine Design” Gives Multiple Myeloma Patient Transplant, Care at HomeSeptember 2nd, 2021
NCCN Releases New Patient Guidelines on Anemia and NeutropeniaMay 3rd, 2021
Join now to see all